Vunakizumab for Radiographic Axial Spondyloarthritis: A Randomized Clinical Trial

Area of Science:

• Rheumatology
• Clinical Trials
• Immunology

Background:

• A significant portion of patients with radiographic axial spondyloarthritis (r-axSpA) show inadequate response or intolerance to current therapies.
• There is a critical need for novel treatments offering sustained disease control in r-axSpA.

Purpose of the Study:

• To assess the efficacy and safety of vunakizumab, an anti-interleukin (IL) 17A monoclonal antibody.
• To evaluate vunakizumab as a potential new therapeutic option for active r-axSpA.

Main Methods:

• A phase 2 to 3, randomized, double-blind, placebo-controlled trial involving 548 adult patients with active r-axSpA across 38 hospitals in China.
• Patients received subcutaneous vunakizumab (120 mg) or placebo, with efficacy assessed via Assessment of Spondyloarthritis International Society response criteria (ASAS20) at week 16 as the primary endpoint.

Main Results:

• Vunakizumab (120 mg) demonstrated a significantly higher ASAS20 response rate at week 16 compared to placebo (65.6% vs 42.5%, P < .001).
• Significant improvements were also observed in ASAS40 response rates and other secondary endpoints, with sustained efficacy through 32 weeks.
• Adverse event incidence was comparable between the vunakizumab and placebo groups during the placebo-controlled period.

Conclusions:

• Vunakizumab (120 mg) significantly improved signs and symptoms of r-axSpA at week 16 compared to placebo.
• The treatment showed sustained efficacy up to 32 weeks and a tolerable safety profile.
• These findings support vunakizumab as a promising new treatment option for active r-axSpA.